Variations in captopril formulations used to treat children with heart failure: a survey in the United kingdom

Mulla, Hussain; Tofeig, Magdi; Bu'Lock, Frances; Samani, Nilesh; Pandya, Hitesh C.
May 2007
Archives of Disease in Childhood;May2007, Vol. 92 Issue 5, p409
Academic Journal
Background and objective: Different liquid formulations of a drug prepared for use in children cannot be assumed to have therapeutic equivalence. The objective of this study was to ascertain the interhospital constancy of unlicensed liquid captopril formulations used to treat children with heart failure in the UK. Design: A questionnaire-based telephone survey. Setting: 13 tertiary paediatric cardiac centres in the UK and 13 large hospitals referring patients to these centres. Participants: The study included pharmacists responsible for providing the pharmaceutical input to children with congenital heart disease or a pharmacist designated to cover paediatric services. Technical staff employed by "specials" manufacturers also participated. Results: Four hospitals dispensed captopril tablets for crushing and dissolving in water before administration; the remaining 22 used nine different liquid formulations of captopril. Only three cardiac centres and their referring hospitals were found to be using the same liquid captopril formulations; 10 centres and their referring hospitals were using completely different captopril formulations. Conclusions: This survey shows that paediatric cardiac centres and their referring hospitals use a variety of unlicensed liquid captopril formulations interchangeably. This degree of inconsistency raises issues about optimal captopril dosing and potential toxicity, such that its use may influence paediatric cardiac surgical and interventional outcomes.


Related Articles

  • Formulation, evaluation and optimization of sustained release matrix tablets of captopril. Pinank, V. Pandya; Vandana, B. Patel; Prajesh, Patel // Journal of Pharmacy & Bioallied Sciences;Mar2012 Supplement, pS77 

    Sustained release matrix tablet is a delivery system by which the drug can be delivered at a controlled rate for long period of time. The present study aims at formulation, evaluation and optimization of captopril matrix tablets. A 32 full factorial design was adopted and all 9 batches were...

  • captopril.  // Royal Society of Medicine: Medicines;2002, p136 

    This article presents information on captopril, an angiotensin converting enzyme inhibitor. The drug is a powerful vasodilator which can be used as an antihypertensive and in congestive heart failure treatment. It is often used in conjunction with other classes of drug, particularly diuretic....

  • Lithium.  // Reactions Weekly;9/30/2006, Issue 1121, p18 

    The article presents a case report on a 48-year-old man who developed cardiomyopathy during treatment with lithium for bipolar I disorder. The man received captopril therapy. For the following 2 years, he was clinically well with no sign of psychiatric or medical symptoms, and his dyspnoea and...

  • β-Adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure? Thireau, Jérôme; Karam, Sarah; Roberge, Stéphanie; Roussel, Julien; Aimond, Franck; Cassan, Cécile; Gac, Arnaud; Babuty, Dominique; Le Guennec, Jean-Yves; Lacampagne, Alain; Fauconnier, Jérémy; Richard, Sylvain // Heart;Jun2014, Vol. 100 Issue 11, p833 

    Aims: Clinical studies failed to prove convincingly efficiency of intravenous infusion of neseritide during heart failure and evidence suggested a pro-adrenergic action of B-type natriuretic peptide (BNP). However, subcutaneous BNP therapy was recently proposed in heart failure, thus raising new...

  • Alpha-Adrenergic Receptor Blockade with Prazosin. Colucci, Wilson S. // Annals of Internal Medicine;Jul82, Vol. 97 Issue 1, p67 

    Characterizes prazosin, an orally active alpha-1 selective adrenergic antagonist drug use in treating patients with hypertension and congestive heart failure. Controversy over the long-term efficacy of the drug in patients with congestive heart failure; Cause of the drug's hemodynamic effects...

  • ALPHA ADRENERGIC RECEPTOR BLOCKERS. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2011, p20 

    The article presents information on alpha adrenergic receptor blockers, a drug developed to treat high blood pressure, congestive heart failure and Raynaud's disease, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other...

  • Acute Titration and Chronic Follow-up with Captopril in Hypertension. A One-Year Safety Profile on Combination Therapy with Captopril and a Diuretic. Mahapatra, Dipta; Mahapatra, Rajat K.; Yaden, Senka; Hunter, Kenneth W. // Angiology;Dec1986 Part 1, Vol. 37 Issue 12, p865 

    The present study examines acute titration with captopril and chronic follow-up data on captopril and a diuretic in patients with all forms of hypertension. Captopril was initiated in those patients in whom previous antihypertensive agents either failed to control high blood pressure or produced...

  • Double-Blind Comparison of Captopril with Nifedipine in Hypertension Complicated by Intermittent Claudication. Roberts, David H.; Tsao, Yvonne; Linge, Keith; McLoughlin, Gerard A.; Breckenridge, Alasdair // Angiology;Sep1992, Vol. 43 Issue 9, p748 

    In a double-blind, crossover trial 12 patients with hypertension and peripheral arterial disease were randomized to three months' treatment with captopril 25-50 mg twice daily or nifedipine SR 20-40 mg twice daily. While both treatments were equally effective at lowering blood pressure,...

  • Hypotensive effects of captopril on physical properties of the arterial system in young and adult rats. Chang, Kuo-Chu; Peng, Ying-I; Tsai, Yuan-Feen; Tseng, Yung-Zu; Chen, Hsing-I // Biogerontology;Jan2001, Vol. 2 Issue 1, p45 

    We determined the acute effects of the angiotension converting enzyme inhibitor captopril on the arterial mechanics in rats at different ages, based on the exponentially tapered T-tube model. Male Wistar-Kyoto rats aged 4 and 12 months were individually referred to as young (n = 8) and adult...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics